Medicare’s Organ Acquisition Payments Under Scrutiny

Medicare’s Organ Payment Discrepancies

A recent audit by the Department of Health and Human Services Office of Inspector General (OIG) uncovered an estimated $380 million to $400 million spent on organs that were never used in Medicare-covered transplants. This revelation has prompted concerns about how Medicare reimburses transplant centers and whether existing guidance conflicts with federal law.

The audit highlighted differences between federal statutory requirements and the guidance issued by the Centers for Medicare & Medicaid Services (CMS). The report found that Medicare reimbursed transplant centers for organs that either ended up with non-Medicare patients or were never transplanted. Michael Ryan, a financial expert, explained to Newsweek, “Medicare was paying acquisition costs under guidance that assumed all organs transferred through the system would be used for Medicare patients. Sometimes they weren’t.” He emphasized the need for alignment between CMS guidance and federal law, noting the impact on taxpayers.

Why It Matters

This audit arrives amidst heightened scrutiny of federal healthcare spending and Medicare’s financial sustainability. In 2023, Medicare reimbursed certified transplant centers over $3 billion for about 39,000 organs, marking organ transplantation as one of its most expensive services. The findings imply that reimbursement practices may not fully align with federal law, posing significant costs to taxpayers.

What To Know

Under federal law, Medicare should reimburse transplant centers only for organs used in Medicare-covered transplants. However, CMS guidance advises centers to treat transferred organs as “Medicare usable,” assuming eventual use in covered procedures. The reality often differs, with some organs aiding non-Medicare patients or remaining unused.

The audit, covering 2017 through 2022, identified conflicts between CMS guidance and statutory requirements. Michael Ryan noted, “For beneficiaries, this might not reflect as a direct charge, but each unwarranted Medicare dollar detracts from actual patient care, compounding financial pressures.”

What the Audit Found

Auditors assessed a sample of 180 organs labeled as Medicare-usable by 12 transplant centers, linked to around $12.3 million in reimbursements. The findings revealed:

• Medicare spent approximately $2.8 million on 55 organs failing federal reimbursement standards.
• Of these, 43 were used in non-Medicare patient procedures, and 12 were left untransplanted.

Based on this, the audit estimated Medicare paid approximately $380 million for organs not used in Medicare-covered transplants over six years. Despite this, Drew Powers of Powers Financial Group remarked, “Spread over six years, a 2 percent waste seems reasonable in the intricate field of organ transplantation.” He pointed out that despite $18 billion spent over six years, the majority was effectively utilized.

Why Did This Happen?

According to the OIG, federal law restricts reimbursement to organs used in Medicare-covered transplants. CMS guidance, however, presumes removed organs will eventually serve Medicare beneficiaries. The audit demonstrates this assumption doesn’t always hold, leading to shared costs for organs not aiding Medicare enrollees.

What Happens Next

The OIG advised CMS to reclaim $154,210 from two transplant centers lacking adequate reimbursement documentation. Additionally, there is a call to revise Medicare guidance to ensure that only organs transplanted into Medicare enrollees are considered and reported as Medicare-usable.